Market Snapshot

European Stocks Close Lower in Thursday Trading Amid World Leader Summit, Anthropic IPO

Back

Last updated: 11/19/2026 11:58:44

11:58 AM EST, 11/19/2026 (MT Newswires) -- The European stock markets closed lower in Thursday trading as investors monitor talks among President Trump, Russian President Vladimir Putin, and Chinese President Xi Jinping, as well as Anthropic's stock market debut.

The Stoxx Europe fell 0.7%, Germany's DAX dropped 0.9%, the FTSE 100 lost 0.8%, France's CAC declined 0.6%, and the Swiss Market Index decreased 0.9%.

The Dutch Data Protection Authority said Thursday that it is advising consumers against buying artificial intelligence camera glasses for general use. It said its own study of six AI camera glasses "shows that these not only endanger the privacy of bystanders but also the safety of users and those around them."

The regulator said that during a simulated CPR scenario, one pair of glasses incorrectly indicated that an ambulance was on its way, even though emergency services had not been alerted. It also found that the glasses failed to sufficiently account for the safety of minors and had security vulnerabilities in their software.

In corporate news, Deutsche Bank's Italian unit concealed up to 800 million euros ($878.7 million) in mortgage-related losses through derivative transactions and accounting adjustments over more than a decade, the Financial Times reported, citing leaked internal documents.

According to the report, an internal investigation, codenamed Project Aetos, found that employees used a hidden reserve, known as "tesoretto," to conceal underperformance and meet profit targets. The unit also entered 900 million euros in derivative positions without economic rationale.

Meanwhile, the German bank also faces an investigation over how it handles client data after millions of its internal records were leaked, Bloomberg reported Thursday, citing a statement by the German state of Hesse's lead data protection official.

Alexander Rossnagel is investigating whether the bank used proper measures to protect data and has asked it to provide more information and access to documents, the report said, which added that the leaks date back several years.

Deutsche Bank and the data protection authority did not immediately reply to MT Newswires' requests for comment.

Shares of Deutsche Bank gained 0.7% in Frankfurt.

Novartis expects net sales to grow at a 5% compound annual rate at constant currencies from 2026 through 2031, the company said Thursday.

The drugmaker also raised peak sales forecasts for three products. It now expects Kesimpta to reach $8 billion, up from $6 billion, while forecasts for Scemblix and Leqvio increased to $5 billion each from $4 billion.

Novartis said its marketed portfolio and pipeline are expected to support sustained mid-single-digit sales growth over the longer term.

Shares of the Swiss pharmaceutical company fell 3% in Zurich.

Sanofi is mulling an acquisition of US drugmaker Insmed (INSM), Bloomberg reported Thursday, citing people familiar with the matter.

Sanofi is in talks with advisers as it evaluates a potential deal for Insmed, the shares of which have dropped about 40% over the last year, giving it a market value of about $26.6 billion, the report said, citing the people.

Deliberations are underway and any deal could still be weeks away, the report said, citing the people.

Insmed declined to comment, while Sanofi didn't immediately reply to a request for comment from MT Newswires.

Sanofi also said Thursday that the European Commission has approved its rabies vaccine, VaxRabeo, for pre- and post-exposure prophylaxis for all age groups in the European Union.

The approval is supported by a clinical program comparing VaxRabeo with Sanofi's current standard-of-care vaccines across all age groups and World Health Organization-recommended schedules, the company said.

Shares of the French pharmaceutical company dropped 2.9% in Paris.

Equinor said in an update Thursday that a cyberattack detected Nov. 17 remains ongoing, though production is running as normal.

The company is working to stop the attack, which does not appear to be specifically targeting Equinor, and restore the full integrity of affected systems in coordination with national security authorities, the company said.

"It is too early to say how long this work will take," the company said. The company added that it had "no indications that data has been stolen or altered."

Shares of the Norwegian petroleum refiner declined 1.2% in Oslo.

UBS plans to shift hundreds of roles across its group functions from Europe to India over the next couple of years as part of a long-term strategy to streamline operations and reduce costs, Bloomberg reported Thursday, citing unnamed people familiar with the matter.

Most affected roles are based in Poland and span group functions, primarily at junior to mid-level, with some senior positions also expected to be hired in India, according to the report.

The planned transfers are separate from the 3,000 job cuts UBS announced in Switzerland as part of its Credit Suisse integration, Bloomberg added.

UBS declined to comment.

Shares of the Swiss Bank were off 0.2% in Zurich.

AstraZeneca said Thursday the US Food and Drug Administration has granted priority review to its biologics license application for sonesitatug vedotin in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma cancers.

The application covers second-line and later treatment of patients whose tumors express CLDN18.2 on at least 25% of tumor cells, the company said.

The FDA's decision is expected in Q2 2027, AstraZeneca said.

Shares of AstraZeneca decreased 2.5% in London.

GSK said Thursday Japan's Ministry of Health, Labour and Welfare granted orphan drug designation to its experimental drug, velzatinib, for the treatment of gastrointestinal stromal tumors.

The company said the designation was supported by data from the ongoing phase 1 trial, which showed anti-tumor activity and a tolerability profile in patients with advanced disease.

Enrollment in the second-line trial is ahead of schedule, with data expected in H2 2027, it added.

Shares of the British pharmaceutical company were down 1.7% in London.

Royal Philips said Thursday that it is introducing Advanced Image Insights on HealthSuite, a cloud-based product combining Philips' visualization applications with the management of third-party AI applications for radiology workflows.

The product will allow workflow automation and will provide analysis results using AI applications, the company said.

Shares of the Dutch healthcare tech conglomerate declined 1.1% in Amsterdam.

http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.




Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.